ChinaBio Today -- Kun Run Biotechnology, a company that focuses on peptide-based drugs, reported that 2008 revenues climbed 56% to $11.6 million. Net income nearly tripled from the year earlier, rising to $6 million or 52% of sales on a non-GAAP basis. Earnings per share were 24 cents, fully diluted. The $6 million net income number includes a $2.4 million extraordinary gain from the sale of property, but does not include a one-time charge for a Make-Good Provision, which reduced earnings by $1.3 million.
